Third Rock Ventures signs AI antibody discovery partnership with Funnel Biosciences worth up to $2.16 billion

Third Rock Ventures has entered a potentially $2.16 billion AI-enabled antibody discovery collaboration with China's Funnel Biosciences, combining epitope-guided molecular design with multiple venture-selected drug targets.

Funnel Biosciences announced a strategic research collaboration with Third Rock Ventures on 6 November 2026, subsequently reported on 9 November, under which the Beijing-based biotechnology company will apply its epitope-guided artificial intelligence antibody discovery platform to multiple drug targets nominated by the US venture capital firm.

The agreement includes an undisclosed platform access fee and potential aggregate payments of approximately $2.16 billion subject to contractual conditions, while Funnel's combination of generative AI and physics-based molecular design is intended to support antibody discovery against challenging targets; the headline value represents contingent potential economics rather than guaranteed upfront consideration.

Field	Content
Article Type	Deals
Research Partner	Funnel Biosciences
Strategic Partner	Third Rock Ventures
Deal Type	Strategic research and AI antibody discovery collaboration
Announcement Date	6 November 2026
Subsequent Industry Reporting	9 November 2026
Agreement Status	Announced
Research Partner Location	Beijing, China
Strategic Partner Location	United States
Technology Platform	Epitope-guided AI antibody discovery
Technology Components	Generative artificial intelligence and physics-based molecular design
Drug Discovery Modality	Antibodies
Research Objective	Discover antibodies against challenging biological targets
Target Selection	Multiple drug targets nominated by Third Rock Ventures
Specific Targets	Not disclosed
Therapeutic Indications	Not disclosed
Platform Access Fee	Payable; amount not disclosed
Maximum Potential Agreement Economics	Approximately $2.16 billion
Contingent Payment Structure	Subject to contractual conditions
Guaranteed Upfront Payment	Not disclosed
Milestone Categories	Not specified in supplied summary
Royalty Terms	Not disclosed
Number of Drug Targets	Multiple; exact number not disclosed
Development Stage	Research and discovery
Clinical Assets Transferred	None specified
Acquisition Involved	No
What Happened	Third Rock Ventures entered a research collaboration with Funnel Biosciences to discover antibodies using an AI-enabled platform.
Why It Matters	The agreement illustrates substantial potential commercial value attached to AI-enabled antibody discovery capabilities.
Strategic Significance	Combines venture-selected therapeutic targets with computational antibody design and discovery technology.
Financial Clarification	The approximately $2.16 billion figure represents potential payments rather than guaranteed upfront consideration.
Transaction Distinction	Research collaboration rather than a company acquisition or regulatory approval.
Key Takeaway	Funnel Biosciences and Third Rock Ventures agreed to collaborate on AI-guided antibody discovery under a potentially multibillion-dollar arrangement.
What to Watch	Disclosure of nominated targets, discovery progress, programme advancement, contractual milestones and subsequent development partnerships.
Submitted Source	Endpoints News
Submitted Source URL	https://endpoints.news/third-rock-enters-2b-partnership-with-ai-focused-chinese-biotech/
Recommended Source	VCBeat Health
Recommended Source URL	https://www.vcbeathealth.com/article/64181
Relevant Date	6 November 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector

• Contact us on: support@nuaxia.com